Yahoo Finance health care correspondent Anjalee Khemlani details how the first case against pharmaceutical company GSK over its Zantac derivative was voluntarily dismissed.
SEANA SMITH: Anjalee, I know you're also following another story. There's an update in the Zantac case that you have for us. What can you tell us?
ANJALEE KHEMLANI: That's right. GSK, the maker originally of that Zantac that spun off Zantac and its consumer health unit did let us know through a statement earlier today that the first case that was supposed to start, the trial supposed to start at the end of the month has, in fact, been filed for voluntary dismissal by the plaintiff.
And so that makes it-- basically drops the first case of the nearly 3,000 that GSK has been named in. This, of course, if you remember, is the concern of how the drug can impact, that heartburn drug can impact humans and whether or not there is a carcinogen threat in there. The FDA as well as other scientific experts have said that there isn't. And so we're just waiting to see whether or not this will impact further cases down the line. The next date on the docket for anything related to these cases is September 20. Back to you.